Aclarion (ACON) Registration Filing summary

Company overview and business model

• Operates as a healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments for low back and neck pain, a $134.5B U.S. market.

• Utilizes AI for quality control and aspires to develop machine learning algorithms for associating MRS data with clinical outcomes.

• Focuses initially on improving surgical outcomes for chronic discogenic low back pain, with plans to expand to conservative therapies and other pain populations.

• Holds a portfolio of 22 U.S. patents, 17 foreign patents, and several pending applications, including exclusive licenses from UCSF.

• Recognized by NIH and included in major research programs and clinical studies, demonstrating improved patient outcomes when its technology is used in surgical decision-making.

Financial performance and metrics

• Qualifies as an emerging growth company and a smaller reporting company, presenting two years of audited financial statements and reduced disclosure obligations.

Use of proceeds and capital allocation

• Net proceeds intended for market development, clinical evidence, product development, quality, general administration, debt retirement, and other corporate purposes.